NCT03906331 2025-01-17
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Eli Lilly and Company
Approved for marketing
Clinical Trials
3 trialsNCT04204928 2021-08-13
Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC
Blueprint Medicines Corporation
Approved for marketing
NCT01683110 2013-01-16
Expanded Access of Cabozantinib in Medullary Thyroid Cancer
Exelixis
Approved for marketing